Exchange: OTC·Updated 02:10 PM EST

CBIH News

News
all
press releases
The regulatory framework for cannabinoid research in the United States is rapidly evolving. A highly anticipated DEA administrative hearing scheduled to begin on June 29, 2026, will evaluate the proposed transition of marijuana from Schedule I to Schedule III. According to official federal notices published by the U.S. Department of Justice, this upcoming proceeding provides a legally compliant pathway to evaluate broader changes to marijuana's status under federal law (Source). For biotechnology entities quietly constructing intellectual property (IP) portfolios around ...
AllPennyStocks.com
The regulatory framework for cannabinoid research in the United States is rapidly evolving. A highly anticipated DEA administrative hearing scheduled to begin on June 29, 2026, will evaluate the proposed transition of marijuana from Schedule I to Schedule III. According to official federal notices published by the U.S. Department of Justice, this upcoming proceeding provides a legally compliant pathway to evaluate broader changes to marijuana's status under federal law (Source). For biotechnology entities quietly constructing intellectual property (IP) portfolios around ...
AllPennyStocks.com

Advertisement|Remove ads.